CLINICAL COMPARATIVE STUDY OF SUMATRIPTAN VERSUS ERGOTAMINE THERAPY IN MIGRAINE

K. V. Giriraja1, Pavitra Chandrashekhar2, Bindumathi P. L.3

1Professor, Department of General Medicine, Sapthagiri Medical College, Bangalore.
2Private Consultant, Ajisha Dental Clinic, Bangalore.
3Professor & HOD, Department of General Medicine, Sapthagiri Medical College, Bangalore.

ABSTRACT

BACKGROUND
Migraine is a common neurological problem accounting for large morbidity and disability. Ergotamine and triptans are mainly used to terminate the attack of severe migraine. To study the clinical comparison between sumatriptan and ergotamine in migraine patients.

AIM
This study compared the safety efficacy and pharmacoeconomics of triptans versus ergotamine therapy.

MATERIALS AND METHODS
Study sample included 100 patients of either gender aged 18 to 65 yrs reporting in Neurology OPD in Sapthagiri Institute of Medical Sciences, Bangalore. The study was conducted from January 2014 to December 2014.

RESULTS
Triptans was found to be more efficacious than ergotamine in curing an attack of migraine and its associated symptoms, but looking into the contraindications, side effects and cost of the triptans, there has been limitations in its prescptions as well as use.

CONCLUSION
Ergotamine is more effective in sustained pain relief with less recurrence rate, less adverse effects and more economical compared to sumatriptan.

KEYWORDS
Migraine, Headache, Sumatriptan, Ergotamine.

INTRODUCTION
As new molecules come to market, they should be more effective in clinical response, have less side effects, less drug interactions, less adverse effects and are more cost effective. Many drugs are available for the treatment of migraine; 5-HT IB/ID agonist; triptans are the new molecules that has come into market. There are many conventional therapies to treat this disorder. Migraine is a complex disorder characterized by recurrent episodes of headache, most of them unilateral and in some cases associated with visual or sensory symptoms collectively known as an aura that arise most often before the head pain, but that may occur during or after. Migraine is most common in women and has a strong genetic component. Typical symptoms of migraine include throbbing or pulsative headache with moderate-to-severe pain that intensify with movement or physical activity. Unilateral or localised pain can occur in the frontotemporal or ocular area, but the pain can be felt in and around the head and neck region. Pain builds up over a period of one to two hours progressing posteriorly and becoming diffuse.1,2,3

Headache lasts for 4 to 72hrs. The other associated symptoms of migraine are nausea 80%, vomiting 50% including anorexia and food intolerance and light headedness, sensitivity to light and sound. Features of migraine may precede or accompany the headache phase or may occur in isolation. Usually develops over 5 to 20 minutes and lasts less than 60 minutes. Most commonly visual, but can be sensory motor or any combination of these. Visual symptoms can be positive or negative. The most common positive visual phenomena is scintillating scotoma. Clinical signs in migraine includes cranial or cervical muscle tenderness, Horner Syndrome, conjunctival injection, tachycardia or bradycardia, hypertension or hypotension, hemisensory or hemiparesis.4-5

The mechanism of migraine remains incompletely understood. Vascular theory proposed in the 1940 and 1950 to explain the pathophysiology of migraine headache. Ischemia induced by intracranial vasoconstriction is responsible for the aura of migraine and the rebound of vasodilatation and activation of perivascular nerves resulted in headache. This theory was based on the following three observations; extracranial vessel become distended and pulsatile during headache; stimulation of intracranial vessels in an awake person includes headache; vasoconstrictors (Ergots) improve the headache whereas vasodilators (Nitro glycerine) provoke an attack.5,6

Neurovascular theory holds that a complex series of neural and vascular events initiates migraine. According to this theory, migraine is primarily a neurogenic process with secondary changes in cerebral perfusion.2,4,5
Cortical Spreading Depression
In 1994, Leo proposed the theory of cortical spreading depression to explain the mechanism of headache with aura. CSD is a well-defined wave of neuronal excite in the cortical grey matter that spreads from its site of origin at the rate of 2 to 6 mm per minute.5,6

Vasoactive Substances and Neurotransmitters
Perivascular nerve activities also result in release of substance such as substance P, neurokinin A and nitric oxide which interact with the blood vessels to produce dilation protein extravasation and sterile inflammation.5,6

Migraine Centre
A potential migraine centre in the brain stem has been proposed based on the PET scan results.

Brain Stem Activation
PET scan in patients having an acute migraine headache demonstrates activation of contralateral pons even after medications abort the pain.

Cutaneous Alloodynia
Burstein described the phenomenon of cutaneous alldynia, in which secondary pain pathways of the trigeminothalamic system become sensitised during a migrainous episode. This observation demonstrates that along with the previously described neurovascular events, sensitisation of the centre pathways in the brain, mediates the pain of migraine.5,6,7

Dopamine Pathways
Some authors have proposed dopaminergic basis for migraine. In 1977, Sicuteri postulated that a state of dopaminergic state of hypersensitivity is present in patients with migraine.6,9,10

Magnesium Deficiency
Another theory proposes that deficiency of magnesium in brain triggers a chain of events starting with platelet aggression resulting in release of 5-HT, which is a vasoconstrictor.11,12,13

Endothelial Dysfunction
Nitric oxide released by microglial is a potentially cytotoxic proinflammatory mediator initiating and maintaining brain inflammation.13,14,15

Serotonin and Migraine
Serotonin receptors are believed to be the most important receptor in the headache pathway. All the currently available triptans are selective 5-HT IB/ID agonist. These agents decrease the headache by abolition in the neuropeptide release in the periphery and blocking neurotransmission by acting on second order neurons in the trigeminal system.16,17,18

Exclusion Criteria
Patients with IHD, congestive heart disease uncontrolled hypertension were excluded also patients having history of epilepsy, basilar migraine, pregnant or lactating mothers were also excluded.

Group A patients were given sumatriptan 15 mgs and Group B patients received ergotamine 1 mg tablets maximum 6 tablets. The next day of taking the drug follow up visit was done. The following outcome measures were defined for the analysis.

Pain Relief
Reduction of headache severity from moderate or severe at base line to mild or none at 2 hours

Pain free
Complete abolition of headache at 2 hrs
Twenty Four hour sustained pain relief: Headache relief at two hours with no recurrence and no use of additional medication from 2 to 24 hrs after the initial dose.

RESULTS
The response to drugs was noted, data tabulated and analysed statistically.

Pain free at 2 hrs: complete abolition of headache at 2 hrs.

<p>| Pain relief at two hours: reduction of headache severity from moderate or severe at baseline to mild or none at 2 hours. |</p>
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain free</td>
<td>1654</td>
<td>24%</td>
</tr>
<tr>
<td>Pain relief</td>
<td>1654</td>
<td>24%</td>
</tr>
</tbody>
</table>

Table 3: The number of percentage of patients who reported occurrence of headache with 24 hrs, i.e., a return to headache severity of grade 2 or 3 in patients who showed an initial response at two hrs. Table 3:

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain free</td>
<td>1654</td>
<td>24%</td>
</tr>
<tr>
<td>Pain relief</td>
<td>1654</td>
<td>24%</td>
</tr>
</tbody>
</table>

DISCUSSION
Freedom from headache and headache relief is higher in sumatriptan, but recurrence of headache within 24 hrs and 24 hr sustained pain relief was better with ergotamine group compared to triptans group. Our study also shows that side effects were less in ergotamine therapy as compared to sumatriptan therapy. Statistically, however, the difference was not significant. Our study shows that effect of 24 hrs sustained pain relief was better in ergotamine group compared to sumatriptan group.
6% had hypertension and tachycardia and 4% had muscle cramps. Cost of aborting the acute migraine attack is rupees 40 for sumatriptan group as compared to rupees 6 for ergotamine group. India is a developing country, 25% live below poverty line.8,9,10,11,12,13 This is lesser than sub-Saharan countries. Hence, conventional ergotamine therapy can be made available in government hospital and physician in general hospital can continue to prescribe the conventional therapy rather the sumatriptan. Patients suffering from headache believe that they are not suffering from any major disorder and hence land up in Government Hospitals. Very few patients approach Private Hospital. Hence making available cheaper and effective less adverse effect producing drugs at Government Hospital is the need of the hour.14,15,16,17,18

CONCLUSION
From our study it was evident that headache relief and freedom from headache was better with sumatriptan compared to ergotamine. But recurrence of headache and sustained pain relief was better with ergotamine compared to sumatriptan. Incidence of drug interaction and side effects was also lesser with ergotamine. Ergotamine is economical compared to sumatriptan. Hence physicians may continue to prescribe ergotamine compared to sumatriptan in government setup.

### Table 1: Showing Distribution of Cases according to time at which they were pain free

<table>
<thead>
<tr>
<th>Time (Hours)</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>2 (3.50%)</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>7 (12.28%)</td>
<td>1 (2.70%)</td>
</tr>
<tr>
<td>1.5</td>
<td>13 (22.80%)</td>
<td>3 (8.10%)</td>
</tr>
<tr>
<td>2</td>
<td>25 (43.85%)</td>
<td>6 (16.2%)</td>
</tr>
</tbody>
</table>

### Table 2: Showing Distribution of Cases according to time at which they achieved pain relief

<table>
<thead>
<tr>
<th>Time (Hours)</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>10 (37.54%)</td>
<td>2 (5.40%)</td>
</tr>
<tr>
<td>1</td>
<td>23 (40.35%)</td>
<td>7 (13.9%)</td>
</tr>
<tr>
<td>1.5</td>
<td>37 (64.91%)</td>
<td>12 (32.43%)</td>
</tr>
<tr>
<td>2</td>
<td>41 (71.92%)</td>
<td>15 (40.54%)</td>
</tr>
</tbody>
</table>

### Table 3: Showing Recurrence of Headache within 24 hrs in Both Groups

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(n=57)</td>
<td>15 (26.3%)</td>
</tr>
<tr>
<td>B(n=37)</td>
<td>5 (13.5%)</td>
</tr>
</tbody>
</table>

REFERENCES